Established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Dr Shisong Jiang – Recombinant Overlapping Peptides (ROP).
Our aim is to develop therapeutic agents for the treatment of cancer based on
the invention of Dr Shisong Jiang – Recombinant Overlapping Peptides (ROP).
These agents are an exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer, making it easier to deliver, more effective and much more economical.
Immunotherapy is effective by activating the immune system to attack tumours directly thus reducing the need for invasive treatments such as chemo and radiotherapy.
Oxford Vacmedix is looking for a large pharmaceutical firm to codevelop its ROP technology, a suitable CMO for GMP-level production for its preclinical/phase 1 vaccine trials in Europe, and firms that can sequence tumor mutations against which it can design personalized vaccines (neoantigens).
The company is also interested in collaborating with organizations that can provide checkpoint inhibitors suitable for combination with ROP vaccines.*
* Text courtesy of BioPharma Dealmakers, September 2017
The immune system employs specialised agents to attack particular targets on invading organisms and tumours. These can be either antibodies or a type of T Cells (often called cytotoxic T Lymphocytes or CTL). These CTLs are produced when a T Cell encounters a protein or other molecule it considers to be foreign and not normally found in the body. The T Cell that recognises these foreign agents is then multiplied to provide a defence against the invading organism or tumour.
All the latest news from Oxford Vacmedix
If you want to have a quick chat, or leave us some feedback,
you can contact us using any of the methods below